Industry Optimism Outweighs Personal Job Security - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Optimism Outweighs Personal Job Security
Restructuring mutes employment optimism.


Pharmaceutical Technology
Volume 37, Issue 12, pp. 32-34
2013 Pharmaceutical Technology Employment Survey
Photo Credit: kizilkayaphotos/Maria Toutoudaki/Getty Images; Dan Ward

Amid the environment of a gradual economic recovery and continued consolidation of bio/pharmaceutical companies, scientists, technicians, and professionals involved in drug development expressed a mix of muted optimism and stagnant employment options. Readers of Pharmaceutical Technology shared their perspectives on the current employment situation in the magazine’s annual employment survey. The respondents represent a cross section of small- and large-molecule drug development functions from facilities in North America, Europe, and other locations. Approximately 60% of the respondents held advanced degrees, divided evenly between Master’s and doctorate degrees.

In 2013, more than half of the respondents said they were involved in a merger, acquisition, downsizing, or restructuring. This represents a significant jump from 2012, when 36.1% of survey participants experienced similar company changes. This activity could be a reason for the slight pullback in confidence in job security.

In the past two years, have you been through a merger, acquisition, down-sizing, or restructuring?

2012

36.1%

63.9%

2013

51.3%

48.7%

 

Since 2010, confidence in job security has trended upward. Four years ago, 53% of the respondents said they were less secure in their position versus the previous year. In 2013, only 37.4% said they were less secure compared to 2012.  However, more respondents felt less secure in their positions in 2013 compared to 2012, illustrating a slight drop in job security confidence.

How secure do you feel in your job compared with the past two years?
How secure do you feel in your job compared with the past two years?
Job security legend

Nearly two-thirds of those surveyed (63.3%) reported a salary increase in 2013. While 43% said they were paid fairly, almost 35% said their compensation was at the lower range of market value. Nearly 20% said they were paid below market value.  More than half reported an increase in the cost of health insurance.

Does your salary reflect a change over last year’s salary?

Increase

63.3%

Decrease

6%

No change

30.7%

 

Rate your satisfaction with your current salary (for your level of expertise and responsibility).

I am paid excessively

2.5%

I am paid fairly

43%

I am paid within market value, but at the low end of the range

34.9%

I am paid below market value

19.7%

 

Within the past two years, has your workload increased, decreased, or stayed the same?
Within the past two years, has your workload increased, decreased, or stayed the same?
Workload legend

However, respondents cited other factors as important to job satisfaction with challenging projects, intellectual stimulation, or good work/life balance as “the main reason I come to work.”

This is the main reason I come to work.
This is the main reason I come to work.

Work/life balance and salary were the two most important reasons respondents would change jobs, followed by job security and professional advancement. More than half were confident that they could find a job comparable to the one they currently hold, although 42% said it would take some time to locate a suitable position.

I would change jobs for this alone.
I would change jobs for this alone.

While respondents had some reservations about prospects for their own positions, they were more optimistic about business prospects for their organizations and the overall bio/pharmaceutical industry. Nearly 60% predicted business prospects for their company will improve in 2014, a jump of 11 percentage points over 2012. The percent of respondents who thought business would decline dropped from 18.1% in 2012 to 13.1% in 2013.

What is your prediction for your company’sbusiness prospects in the coming year?
What is your prediction for your company’s business prospects in the coming year?

When considering the outlook for the overall bio/pharmaceutical market in the short- and long-term, 54.3% of the respondents predicted that business will improve, versus less than 6% who expect a decline in business. Interestingly, more survey participants expect business to improve overseas but not domestically (16.5%), versus those that expect improved conditions domestically, but not overseas (2.9%).

In your view, what is the general outlook for the bio/pharmaceutical industry in the short- and long-term?
In your view, what is the general outlook for the bio/pharmaceutical industry in the short- and long-term?

In evaluating the capabilities of new hires in the bio/pharmaceutical industry, 79% of those surveyed said the new employees were adequately trained, but not exceptional. More than 13% said the new hires were poorly trained.

Reference
1. 2013 Pharmaceutical Technology Employment Survey.

Note: Due to rounding, some percentages may not add up to 100%. Some questions allowed multiple answers.

 

 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here